Background. Normally, humans are protected against infections by their anaerobic intestinal microorganisms providing colonization resistance. In immunocompromised patients, the endogenous intestinal gram-positive and gram-negative pathogens often cause infectious complications. Therefore, we analyzed the effect of chemotherapy treatment and antimicrobial prophylaxis on intestinal bacterial populations (microbiota) among pediatric patients with acute myeloid leukemia who are prone to intestinal mucositis and infections.
of prophylactic antibiotics and early empirical use of broad-spectrum antibiotics for febrile neutropenia [1] . Evidence indicating an endogenous origin of gram-negative and gram-positive bacteremia is increasing [2, 3] . To prevent the invasion of endogenous bacteria from the oral cavity and the gastrointestinal tract, 3 defense mechanisms are considered to be relevant: innate immunity, mechanical mucosal barrier, and colonization resistance. Since 1966, it has been known that the main parameters in innate immunity are the duration and nadir of neutropenia, both of which are associated with an increased risk of infection [4, 5] . Nowadays, attention is drawn toward mucositis, as caused by chemo- therapy and radiotherapy, as an independent risk factor for infectious complications [6, 7] .
This article focuses on colonization resistance, the third defense mechanism for the prevention of translocation of enteropathogenic bacteria. Colonization resistance is the beneficial effect of the predominantly anaerobic resident microbiota of the gastrointestinal tract, which, by their sheer numbers, provide resistance toward invasion and/or outgrowth of potentially pathogenic bacteria from both the environment and the host's own intestine [8, 9] . An adequate characterization of intestinal microbiota is necessary to investigate the supposed relationship among colonization resistance, mucositis, intestinal inflammation, and infection. Previous studies have investigated the effect of chemotherapeutics and/or antibiotics on intestinal microbiota [10] [11] [12] . However, most of these studies were hampered by the restrictions of culturing techniques, because a large fraction of intestinal bacteria has never been cultured and thus escape detection. The introduction of DNA-based techniques has made it possible to analyze the host's intestinal microbiota independent of culturing techniques [13, 14] . Denaturing gradient gel electrophoresis (DGGE) is a sequence-dependent method to separate amplified microbial DNA. The resulting fingerprint can be used to qualitatively analyze and compare samples containing a diversity of microbiota. Fluorescent in situ hybridization (FISH) with specific oligonucleotide probes aimed at bacterial ribosomal RNA can be used to determine specific bacterial groups quantitatively.
Changes in the intestinal microbiota during chemotherapy treatment might influence colonization resistance, thereby increasing the risk of infection. Therefore, we characterized the qualitative and quantitative changes in the intestinal microbiota and their causes, using DNA-based techniques, among a cohort of pediatric patients with acute myeloid leukemia (AML), known for their high risk of infection and gastrointestinal complications. [15] . All patients received antibiotic prophylaxis aimed against gram-negative bacteria and fungi (treatment with oral colistin, neomycin, and amphotericin B or with ciprofloxacin and itraconazol), viridans group streptococci (oral phenethicillin), and Pneumocystis jiroveci (oral cotrimoxazol). Febrile neutropenia was empirically treated with both vancomycin and ceftazidime. Feces was collected during 4 consecutive chemotherapy cycles (ADE I, ADE II, MACE, and MidAC; figure 1). Early samples were collected on day 2 (25th-75th percentiles, days 1-3) after the start of a cycle. Late samples were collected on day 11 (25th-75th percentiles, days 9-13). An end-of-treatment sample was collected at least 6 weeks after the end of treatment.
MATERIALS AND METHODS

Subjects
To show the high intraindividual similarity between fecal samples, 11 samples from a single healthy volunteer were collected during a 2-month period. Patients' FISH results were compared with the FISH results for fecal samples from healthy volunteers, previously collected and analyzed in our laboratory [16] . To determine the effect of phenethicillin treatment on intestinal microbiota, 4 healthy volunteers took phenethicillin at a dosage of 500 mg twice a day for 7 days. Fecal samples were collected before and after treatment.
Fecal samples. For storage, aliquots were frozen at -80ЊC. One aliquot of each sample was dried using a freeze dryer (Christ Alpha; Salm and Kipp) to determine the wet-to-dry weight ratio, which was needed to calculate the number of bacteria per gram of dry weight feces, to compensate for a dilution effect due to diarrhea.
DNA extraction from fecal samples. DNA was extracted using a DNA stool mini kit (Qiagen), in accordance with the manufacturer's protocol, with 2 minor modifications. To im- prove the lysis of gram-positive bacteria, the temperature was increased to 95ЊC. Second, the amount of elution buffer was decreased to 30 mL, to increase the final DNA concentration.
Polymerase chain reaction (PCR). For the amplification of bacterial DNA, the universal bacterial primers described by Watanabe et al. [17] were used. To make the PCR product eligible for DGGE, a previously described GC clamp was added to the forward primer [13] . The PCR reaction mixture contained 5 mL reaction buffer (Fermentas Life Sciences), 1.25 U Taq polymerase (Fermentas Life Sciences), 1.5 mmol/L MgCl 2 , 400 nmol/L of both primers, 200 mmol/L of deoxyribonucleotide triphosphate, 0.5 mL bovine serum albumin (10 mg/mL; New England Biolabs), and 20 ng of template DNA in 50 mL. The temperature profile included 2 min at 94ЊC, followed by 40 cycles at 94ЊC for 45 s, 49ЊC for 30 s, and 72ЊC for 1 min, followed by 5 min at 72ЊC. After gel electrophoresis, the ethidium bromide-stained PCR products were analyzed by ultraviolet light.
DGGE. DGGE of the PCR products was performed as described by Muyzer et al. [13] , using a PhorU system (Ingeny). Depending on the concentration, 1-15 mL of PCR product was loaded on a 8% (weight/volume) polyacrylamide gel with a 10%-60% denaturing gradient (100% denaturant equals 7 mol/ L urea and 40% formamide). Electrophoresis was performed for 16 h at 120 V at 60ЊC. Gels were stained with silver nitrate as described elsewhere [18] .
FISH. Fecal samples were 0-10 times diluted in phosphate buffered saline (8 g NaCl, 0.2 g KCl, 1.44 g Na 2 HPO 4 , and 0.24 g KH 2 PO 4 , each per liter), dependent on liquidity. FISH was performed on glass slides as described elsewhere [19] , except Figure 2 . A, Example of polymerase chain reaction (PCR) denaturing gradient gel electrophoresis (DGGE) fingerprints of fecal microbiota of samples collected from 1 patient during chemotherapy cycles I-IV, showing decreasing bacterial diversity and low similarity in species composition during treatment. Consecutive samples are compared with the end-of-treatment samples, resulting in the depicted percentage similarities. AB, antibiotics; N, the sample collected 6 weeks after the end of treatment. B, PCR-DGGE fingerprints of fecal microbiota of 11 samples collected serially during a 2-month period from a single healthy control individual. DGGE fingerprints show a high diversity of bacterial species in every lane and a high similarity between the consecutive lanes. The percentages reflect the measured similarity between the different microbial fingerprints, compared with that of sample 1.
that fixed samples were diluted in phosphate buffered saline instead of Tween 5%. Glass slides were hybridized for 16 h with the probes listed in table 1 or for 2-3 h in the case of the Bac303 and Ec1531 probes [20] [21] [22] [23] [24] [25] [26] . Before hybridization with Enfl3,Enfm2, and Strc493, samples were treated with lysozyme to permeabilize the cell wall, as described elsewhere [22] . After incubation, slides were washed, air dried, and mounted with Vectashield (Vector Laboratories). Bacteria were counted visually using an Olympus BH2 epifluorescence microscope. At least 10 microscopic fields were counted or as many fields as needed to obtain a total number of at least 300 positive bacteria (to a maximum of 25 fields). The total number of bacteria was determined by the bacterial count with the universal Eub338 probe, enumerated with the counts of the Strc493, Enfm2, and Enfl3 probes, because their target species do not hybridize with the Eub338 probe without permeabilization. Obligate anaerobic bacteria are referred to as anaerobes. Facultative aerobic and oxygen tolerant bacteria are referred to as aerobes.
Chemotherapeutics and bacterial growth. Bacteria, previously isolated from clinical samples, were cultured in their appropriate medium by use of standard laboratory procedures [27] . Inoculation was done by diluting bacterial cultures 100 times in their corresponding medium.
Anaerobic bacteria were incubated and cultured using an NOTE. Time points are the beginning and end of 4 consecutive chemotherapy cycles, and they identify whether samples were taken before (early) or after (late) the 4 consecutive chemotherapy courses. The similarity between the samples collected at these 8 time points are compared with the end-oftreatment sample. ADE I and ADE II, high-dose cytarabine, daunorubicine, and etoposide; MACE, amsacrine, high-dose cytarabine, and etoposide; MidAC, mitoxantrone and high-dose cytarabine.
anaerobic hood (Concept 400; Ruskinn Technology Limited). To determine the effect on bacterial growth, different concentrations of the chemotherapeutics were added to the culturing media, as listed in table 2. The concentrations of added chemotherapeutics were determined on the basis of relevant plasma levels [28] [29] [30] . Bacterial growth was quantified by the increase in absorbance of the samples at 492 nm, determined after 24 h of incubation at 37ЊC, with use of a photospectrometer (Vitatron Nederland), relative to a control, which contained the appropriate culturing medium and bacteria but no chemotherapeutic agents.
Data analysis. Intrapatient differences in numbers of bacteria at different time points were compared using the Wilcoxon rank test for paired data. Nonrelated samples were tested using the Mann-Whitney U test, with use of SPSS, version 16.0 (SPSS). A P value !.05 was considered to be statistically significant. For the analysis of fecal DGGE fingerprints, the similarity was calculated on the basis of a Pearson correlation coefficient with use of Gelcompar II (Applied-maths).
RESULTS
Subjects
During 36 chemotherapy cycles, a total of 72 fecal samples were collected from 9 pediatric patients with AML who each received 4 consecutive chemotherapy courses (figure 1). Using National Cancer Institute adverse events criteria [31] , intestinal mucosal barrier injury grade I-III was found after 55% of chemotherapy cycles (grade III-IV was found in 4 [20%] of 20). The highest rate of intestinal mucosal barrier injury was found for chemotherapy cycle I (6 of 9 patients) and cycle III (5 of 6 patients).
Comparison of Intestinal Microbiota PCR-DGGE Fingerprints
The diversity of intestinal microbiota in serially obtained fecal samples was severely limited in the early and late samples, compared with the end-of-treatment sample ( figure 2A) . Each lane of a PCR-DGGE gel represents a microbial fingerprint of a fecal sample; each band within a lane corresponds to 1 bacterial species, although different species may sometimes be represented by 1 band. A band at the same height in different lanes is considered to be the same bacterial species. During chemotherapy treatment, a large decrease in bacterial diversity was seen. Before a new chemotherapy course, the bacterial diversity was restored partially. The median similarity between early and late samples in the patient population was low, in the range 16.8%-64.7% (table 3), which was in clear contrast to the high similarity found among 11 samples collected in a single healthy volunteer (figure 2B). The measured similarity between the early and late samples, on the one hand, and the end-of-treatment sample, on the other hand, was even lower, in the range 16.6%-36.5% (table 3) .
The fingerprint of the end-of-treatment sample showed a diversity comparable to that for a healthy control sample (data not shown). Because of the high interindividual variety in PCR-DGGE profiles, patient samples were not compared with samples from healthy controls [32] .
The effect of empirical treatment with broad-spectrum antibiotics. Analyzing the 12 chemotherapy cycles in which no therapeutic antibiotics were given, no significant difference was found in median similarity between early and late samples (median, 52.4%; range, 11.5-86.1), compared with the median similarity in the cycles with empirical antibiotic treatment (median, 31.9%; range, 8.8-72.5).
The effect of phenethicillin on gut microbiota. In 4 healthy control individuals, we studied whether phenethicillin treatment might be related to a decreased microbial diversity. In comparison of fecal microbial fingerprints for samples collected on day 0 and day 7, a median similarity of 74.2% (range, 61.2%-80.5%) was found, which is higher than the median similarity for the patient samples.
Quantitative Analysis of Intestinal Microbiota by FISH
At all time points during treatment (early and late samples), the total number of bacteria was significantly lower, compared with the healthy control samples (P values ranged from .000 to .001) ( figure 3A) . No difference in total numbers was found between end-of-treatment samples and healthy control samples, indicating a restored total number of bacteria at 6 weeks after the last chemotherapy cycle. No significant differences were seen between the consecutive early and late samples. ), except for enterococci in the late 1 sample ( ). Significant differences between end-of-treatment P ! .05 P p .08 samples and healthy control samples were found in enterococci and streptococci but not in the total number of bacteria, anaerobes, or Enterobacteriaceae.
Number of anaerobic bacteria. The median number of 4 predominant groups of intestinal anaerobic bacteria-Bacteroides species, Clostridium cluster XIVa, Faecalibacterium prausnitzii, and Bifidobacterium species-decreased 3000-6000-fold in samples during treatment, compared with the healthy control samples ( figure 4) . Depending on the different time points, this resulted in a 70-20,000-fold decrease in the total number of anaerobic bacteria (P values ranged from .000 to .004) (figure 3B). A recovery was found for both Clostridium XIVa and F. prausnitzii, at 6 weeks after treatment (figure 4). In contrast, the total numbers of both Bacteroides and Bifidobacterium species were still 10-300-fold lower in the end-of-treatment samples, compared with the healthy control samples ( figure 4) . The total number of anaerobic bacteria did not differ significantly between the end-of-treatment samples and the healthy control samples.
Number of aerobic bacteria. In agreement with the prophylactic use of ciprofloxacin, no gram-negative Enterobacteriaceae were detected in any of the fecal samples collected during treatment ( figure 3C ). The number of enterococci was ). Significant differences between end-of-treatment samples and healthy control samples were found in bifidobacteria and Bacteroides P ! .05 species but not in Clostridium XIVa and F. prausnitzii. significantly higher in patient samples, compared with healthy control samples, at 7 of 8 time points during treatment (samples early 1, early 2, late 2, early 3, late 3, early 4, and late 4) and the end-of-treatment sample (P values ranged from .001 to .038) ( figure 3D ). In contrast, a 100-1000-fold decrease in the number of streptococci was found in patient samples, compared with healthy control samples (P values ranged from .000 to .016) ( figure 3E ). The number of streptococci had still not recovered at 6 weeks after treatment. It is noteworthy that microscopic analysis showed that some samples contained only aerobic cocci; the fecal microbiota contained up to 88% enterococci or up to 100% streptococci, which was consistent with DGGE fingerprints showing 1 dominant species.
Chemotherapy and Bacterial Growth
To determine whether the decrease in the numbers of bacteria was a result of chemotherapy, the sensitivity of different bacterial species to chemotherapeutics used in 11 chemotherapy cycle-daunorubicine, etoposide, and cytarabine-was determined. In vitro, both daunorubicine and etoposide showed a negative effect on the growth of both anaerobic and aerobic bacteria (table 3) . Use of a higher concentration of etoposide, but not daunorubicine, resulted in a further decrease in bacterial growth. In contrast, cytarabine showed no effect on the growth of the tested bacterial strains.
DISCUSSION
We showed devastating effects of anticancer treatment on intestinal microbiota in patients with AML. The microbial diversity was low during treatment, and consecutive samples showed considerable variations in microbial fingerprints, as demonstrated using PCR-DGGE. This is in sharp contrast with healthy individuals, in whom a very stable intestinal microbiota is seen [32] . The diversity was lowest during chemotherapy cycles I and III, which also showed the highest incidences of intestinal toxicity. This finding is in line with data from the literature showing that these 2 chemotherapy cycles, in particular, cause intestinal toxicity and infection [33] .
The dramatic decrease found in the number of anaerobic bacteria might have a large impact on colonization resistance. It might also result in an unfavorable effect on intestinal bu-tyrate production, an essential trophic factor for the formation of enterocytes and an important inhibitor of local inflammation, which could further increase the risk of bacterial translocation and infection in neutropenic patients with mucosal barrier injury [34, 35] .
The increase in enterococci during treatment for AML might imply an increased risk of infection with vancomycin-resistant enterococci, because all patients with AML are given empirical treatment with vancomycin during periods of febrile neutropenia [36] [37] [38] . For this small group of patients, we could not test this hypothesis, making it a focus for further research.
Several factors can be responsible for the decrease in both diversity and number of intestinal microbiota in patients with cancer: (1) nasal tube feeding, (2) (prophylactic) antibiotic treatment, and (3) chemotherapy itself [10, 30, 39] .
First, prior research suggests that nutrition is, at best, partly responsible for the devastating effect on microbiota in pediatric patients with cancer [39, 40] . Second, in our study, the devastating effect on the intestinal microbiota cannot be contributed to solely by the use of prophylactic antibiotics, because the diversity of bacteria differed between the early and late samples in all 4 chemotherapy cycles, although prophylaxis was not discontinued between them. Moreover, in another study, only a small effect of oral ciprofloxacin treatment on intestinal microbiota was found [41] . In addition, we found only a small effect of oral phenethicillin treatment on the composition of fecal microbiota in healthy volunteers. Thus, we conclude that the devastating effect on microbial colonization cannot be exclusively caused by the use of prophylactic antibiotics. The effects on intestinal microbiota also cannot be ascribed to the use of broad-spectrum antibiotics in cases of febrile neutropenia, because a low similarity in microbial fingerprints between early and late samples was found, irrespective of the use of these antibiotics. The third possible cause, chemotherapy itself, was tested in vitro. Both daunorubicine and etoposide showed a direct negative effect on bacterial growth. A direct effect of cytarabine was not seen, which might be explained by the fact that only its metabolites exert cytotoxic activity [42] . Unfortunately, with the currently available laboratory techniques, it is not possible to test chemotherapeutic levels in feces, which complicates the interpretation of the results found in this study. However, even the lowest dosages of chemotherapeutics tested inhibited bacterial growth, suggesting an effect on intestinal microbiota in vivo. The impact of chemotherapeutic drugs on colonization resistance will need further research.
In this study, multiple statistical tests were performed for a small population of patients. This could introduce false-positive results. However, even after stringent Bonferroni correction for multiple testing, the decrease in anaerobic bacteria stayed statistically significant, although changes in the numbers of both streptococci and enterococci were no longer significantly different between patient samples and healthy control samples. However, this did not change the overall conclusion of the study-the number of anaerobic bacteria decreases during treatment for AML, thereby increasing the proportion of aerobic and potentially enteropathogenic bacteria, such as enterococci.
To our knowledge, we are the first to demonstrate, using molecular detection techniques (DGGE and FISH) instead of classic culturing techniques (with their drawbacks), that the combination of chemotherapeutics, antibiotics, and artificial feeding has a large effect on the intestinal microbiota. Further research will have to be done to show whether changes in bacterial colonization play a role in the development and maintenance of mucosal barrier injury, infection, and inflammatory syndromes and whether there might be a role for the use of prebiotics, probiotics, and bacterial products, such as butyrate, to prevent mucosal barrier injury and its complications.
In conclusion, a tremendous decrease in intestinal microbial diversity was found in patients with AML during treatment, with a disturbed balance between aerobic and anaerobic bacteria in favor of potentially pathogenic gram-positive aerobic cocci. These changes in microbiota lower the resistance to pathogen colonization. We expect that the diminished colonization resistance increases the risk of gram-positive aerobic infection in immunocompromised patients.
